Recently, we have observed in patients with ovarian carcinoma an association between intestinal permeability and prognosis and a correlation between urinary neopterin and parameters of intestinal permeability. In order to examine prognostic significance of intestinal permeability in a different group of patients, we have retrospectively analyzed pretreatment parameters of gastrointestinal permeability and urinary neopterin in 21 consecutive patients with metastatic colorectal carcinoma treated with the combination of cetuximab, irinotecan, leucovorin and 5-fluorouracil. Neopterin was determined by high-performance liquid chromatography, and gastrointestinal permeability was assessed by measuring, using capillary gas chromatography, urinary sucrose, lactulose, xylose, mannitol and sucralose after oral challenge. Pretreatment sucrose/mannitol ratio equal or above 0.04 (median survival 10.6 vs. 18.4 months; p = 0.03), sucrose/xylose equal or above 0.02 (12.1 vs. 19 months; p = 0.04) and urinary neopterin equal or above 220 µmol/mol creatinine (10.6 vs. 18.4 months; p = 0.02) were indicative of poor survival. A significant correlation was observed between urinary neopterin and sucrose/xylose ratio (rs = 0.57, p = 0.007), while correlation between urinary neopterin and sucrose/mannitol ratio (rs = 0.38, p = 0.096) was of borderline significance. In conclusion, present data demonstrate that gastrointestinal permeability is associated with systemic immune activation and may be of prognostic significance in patients with metastatic colorectal carcinoma.
Introduction
The term intestinal permeability is used to describe the barrier function of bowel mucosa, both in a metabolic and immunologic sense. Derangements of intestinal permeability have been described in patients with cancer, and further changes are known to occur during anticancer therapy (1) . Recently, we have observed an association between intestinal permeability and prognosis in patients with ovarian carcinoma (2) . The prognostic significance of intestinal permeability could be explained by an association between changes in intestinal permeability and systemic immune or inflammatory response. In fact, we have recently reported a correlation between urinary neopterin and parameters of intestinal permeability in patients with ovarian carcinoma (3) . The prognostic significance of increased urinary neopterin has been previously characterized both in gynecological tumors (4) as well as in metastatic colorectal carcinoma (5) .
In order to examine prognostic significance of intestinal permeability in a different group of patients, we have retrospectively analyzed pretreatment parameters of intestinal permeability and urinary neopterin in 21 consecutive patients with metastatic colorectal carcinoma treated with the combination of cetuximab, irinotecan, leucovorin, and 5-fluorouracil.
Patients and Methods
Twenty-one consecutive patients with metastatic colorectal carcinoma, 14 males and 7 females, aged 62 ± 11 (range 36 -75) years, were included in the study. The patients were treated with the combination of cetuximab (loading dose 400 mg/m 2 , subsequently 250 mg/m for 46 hours) every 2 weeks (6), including one patient who received a modification of this regimen. All patients had been previously treated with oxaliplatin, and all but one patient had been pre-treated with an irinotecan-containing regimen. Before therapy, testing for gastrointestinal permeability and evaluation of urinary neopterin was performed in all patients. The protocol was approved by institutional ethical committee, and the patients signed informed consent.
To assess gastrointestinal permeability, a pretest urine sample was collected after an overnight fast to detect any endogenous mannitol. The patients then ingested 100 ml of the test solution containing 2 g of mannitol, 2 g of xylose, 10 g of lactulose, and 25 g of sucrose in water, and 1 g of sucralose in capsules. The patients continued fasting for 2 hours, and urine was collected in two portions for 5 hours and for subsequent 19 hours. Lactulose, xylose, sucrose, sucralose and mannitol were determined by capillary gas chromatography, and urinary excretion was expressed as percentage of the ingested dose of sucrose and sucralose, and as the lactulose/mannitol, sucrose/mannitol, sucrose/xylose and sucralose/mannitol ratios. Urine samples were stored at -24°C until analysis.
The analyses for determination of mannitol, xylose, sucrose, sucralose and lactulose in urine were performed as described (3, 7) . All chemicals were obtained from Sigma (St. Louis, MO, USA). Samples were thawed, spiked with internal standard (phenyl-β-D-glucoside) and evaporated under vacuum to dryness (Eppendorf Concentrator 5301, Eppendorf, Hamburg, Germany). The dried residues were derivatized by hydroxylamine in pyridine (75°C for 30 minutes) and bis(trimethylsillyl)trifluoracetamide (75°C for 15 minutes). The aliquot of the sample was injected into gas chromatograph equipped with a non-polar column and a flame ionization detector (GC 8000, Fisons Instruments, Milano, Italy). Chromatographic data were collected using Clarity software (DataApex, Prague, Czech Republic). The method is specific as no interfering peaks were found, and other mono-and disaccharides did not interfere with the sugars used for gastrointestinal and colonic permeability testing. The detection limit (10 mg/l) and quantitation limit (50 mg/l) for mannitol, xylose, sucrose, sucralose and lactulose were identical, and reproducibility calculated as coefficient of variation was consistently below 7%. The quality control was performed by the measurement of customized stored quality control samples along with each set of samples.
Urinary neopterin was determined as described (5) . Briefly, urine sample were collected and stored at -20°C until analysis. After centrifugation (5 minutes, 1300 g) and diluting 100 µl of urine specimens with 1.0 ml of mobile phase containing 2 g of disodium-EDTA per liter, samples were injected onto a column, and neopterin was determined using high performance liquid chromatography system Prominence LC20 (Shimadzu, Kyoto, Japan). Neopterin was identified by its native fluorescence (353 nm excitation, 438 nm emission wavelengths) and quantified by external standard method. Creatinine was determined by Jaffé reaction after dilution of the sample 1:50 on a Modular analyzer (Roche, Basel, Switzerland) using a commercial kit according to the manufacturer's instructions, and neopterin concentrations were expressed as neopterin to creatinine ratio (µmol/mol creatinine).
The survival of patients with lactulose/mannitol equal or above 0.04, sucrose/mannitol equal or above 0.04, sucrose/xylose equal or above 0.02, sucralose/mannitol ratio equal or above 0.17 and urinary neopterin equal or above 220 µmol/ml creatinine was compared to the survival of patients with lower value of the respective parameters by the log-rank test. These cutoff limits were selected based on medians of respective parameters in the studied group. The correlation was examined by Spearman correlation coefficient. All statistical analyses were performed using NCSS software (Number Cruncher Statistical Systems, Kaysville, Utah, USA).
Results
At the time of analysis, 18 patients died, and 3 patients were alive, 29 -31 months after the start of therapy. The median survival was 12.5 months. Pretreatment sucrose/mannitol ratio (in 5 hour collection) equal or above 0.04 (median survival 10.6 vs. 18.4 months; p = 0.03; Figure 1 ), sucrose/xylose equal or above 0.02 (12.1 vs. 19 months; p = 0.04) and urinary neopterin equal or above 220 µmol/mol creatinine (10.6 vs. 18.4 months; p = 0.02; Figure 2 ) were also indicative of poor survival. In contrast, lactulose/mannitol and sucralose/mannitol ratios were not associated with survival. A trend for lower urinary neopterin concentrations and lower sucrose/mannitol, sucrose/xy-lose and lactulose/mannitol ratios was observed in patients surviving 15 months and longer (Table 1) .
A significant correlation was observed between urinary neopterin and sucrose/xylose ratio (r s = 0.57, p = 0.007; Figure 3 ), while correlation between urinary neopterin and sucrose/mannitol ratio (r s = 0.38, p = 0.096) was of borderline significance. derangement of gastroduodenal permeability. Increased lactulose/mannitol ratio, that reflects changes in the permeability of small bowel mucosa, was not indicative of prognosis in the present cohort that was, however, of limited size. A significant correlation was observed between sucrose/xylose ratio and urinary neopterin, and the correlation between sucrose/mannitol and neopterin was of borderline significance. A trend for higher neopterin and parameters of gastrointestinal permeability in patients surviving less than 15 months has not reached statistical significance, probably due to the limited size of the cohort. Urinary neopterin is an indicator of systemic immune response. In earlier studies in patients with colorectal carcinoma, increased urinary neopterin was associated with inferior prognosis in both univariate and multivariate analyses (5, 8) . Present data indicate that systemic immune and inflammatory response in cancer patients is associated with increased permeability of gastrointestinal mucosa, and this association may explain the prognostic significance of increased gastrointestinal permeability. The measurement of gastrointestinal permeability has been used to follow the changes of bowel function associated with therapy (1).
More recently, we have demonstrated that increased lactulose/mannitol ratio may predict the toxicity of cytotoxic chemotherapy (9) . The measurement of gastrointestinal permeability could thus represent a useful laboratory method for follow up of cancer patients. However, the measurement of intestinal permeability is relatively demanding in terms of logistics. Neopterin correlates with the parameters of gastrointestinal permeability (3) and has been shown to be prognostic factor (5, 8) and a predictor of toxicity (3) . Therefore, measurement of neopterin could be more practical, especially if repeated measurements are required. Moreover, present data indicate that urinary neopterin is indicative of prognosis not only in cancer patients before the start of therapy, but also in patients before the subsequent lines of treatment, including the combination of chemotherapy and biological therapy, in this case the combination of cetuximab and chemotherapy. Present data are retrospective, i.e. hypothesis-generating, and should obviously be reproduced in a larger prospective cohort.
In conclusion, present data demonstrate that gastrointestinal permeability is associated with systemic immune activation and may be of prognostic significance in patients with metastatic colorectal carcinoma. Urinary neopterin is a prognostic factor also in patients treated with the combination of cetuximab and chemotherapy.
